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Abstract
In type 1 diabetes, various metabolic disturbances are frequently observed. Importantly, these may negatively
affect individuals’ long-term health outcomes. The use of probiotics has, in other populations, been beneficially
associated with many of these risk factors. We, therefore, assessed the cross-sectional associations between the
use of probiotics-containing food products or supplements and various health markers in a large population of
individuals with type 1 diabetes.
Included were 1039 individuals (mean age 46 ± 14 years, 45% men) with type 1 diabetes and without end-stage
renal disease. Based on the entries in the diet questionnaire and the food record, participants were divided into
those using (Probioticsyes) and not using (Probioticsno) probiotics-containing products. Various standard health
markers, such as weight, waist circumference, blood pressure, blood lipids, and HbA1c, were measured during the
study visit.
In all, 403 (39%) individuals reported using probiotics. Adjusted with potential confounders, the rate of overweight/
obesity, body mass index, and waist-to-hip ratio were higher in the Probioticsno group. Moreover, the odds of
metabolic syndrome, and its waist, blood pressure, HDL-cholesterol, and triglyceride components were higher
amongst those not using probiotics. In the normal-weight individuals, using probiotics was associated with
significantly better glycaemic control.
Using probiotics-containing food products or supplements may beneficially affect many of the traditional risk
factors related to the diabetic complications. Randomized controlled trials are required to verify these observations.
Keywords: Glycaemic control; Lipid profile; Metabolic syndrome;
Obesity; Probiotics; Type 1 diabetes
Introduction
Diabetes is characterized by pathologically increased plasma glucose
levels [1]. Importantly, hyperglycaemia is an independent risk factor
for the development of vascular complications [2] and mortality [3]. In
addition to glycaemia, however, various other metabolic abnormalities
are frequently present in diabetes. In one Finnish study, 55% of
individuals with type 1 diabetes, for example, failed to meet the LDL-
cholesterol concentration goals [4]. We have also previously shown, in
the Finnish Diabetic Nephropathy (FinnDiane) Study that, of the
individuals with type 1 diabetes and without diabetic nephropathy,
only 35% reached the target levels for the LDL-cholesterol
concentration [5]. In the same study, of the diabetic nephropathy-free
individuals with type 1 diabetes, 45% were observed to reach the blood
pressure targets, while the respective figure for those with diabetic
nephropathy was only 19% [5]. In one review, the reported rates of
obesity or overweight, among adult individuals with type 1 diabetes,
ranged between 44% and 78% [6]. These risk factors, especially the
clustering of multiple risk factors, are associated with increased risk of
various vascular complications [7], detrimental to the longevity of the
affected individuals [8].
The importance of managing these risk factors is stressed in various
national and international treatment guidelines [9-11]. According to
these guidelines, lifestyle management is a fundamental aspect in
diabetes care, and includes components such as nutrition therapy,
physical activity, and smoking cessation. Beyond lifestyle modification,
however, pharmacological approaches are frequently required in order
to achieve the treatment goals.
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The role of the intestinal microbiome, in modifying various
metabolic risk factors, has in recent years gained increasing interest. In
the human intestine, Bacteroidetes and Firmicutes form the majority of
the total microbial population [12]. The relative abundance of these
phyla has, however, been observed to differ between lean and obese,
with higher proportion of Firmicutes to Bacteroidetes in the obese
[13]. Moreover, lower bacterial richness in the human gut has been
associated with markedly higher body weight and fat mass [14]. In
addition to the body weight-related variables, the quality of the
intestinal ecosystem has been associated with systemic inflammation,
plasma lipids, glycaemia, and blood pressure [14-16].
Probiotics-containing food products or supplements have been used
to favourably modify the gut’s microbial composition [17]. According
to the definition, published by the joint Food and Agriculture
Organization/World Health Organization Expert Consultation,
probiotics are “live microorganisms which when administered in
adequate amounts confer a health benefit on the host” [18]. These
health benefits have been investigated in various populations. For
example, in a meta-analysis of nine randomized controlled trials
among adults with or without hypertension, probiotic interventions
were observed to reduce systolic and diastolic blood pressure [19]. In
another meta-analysis of individuals with high, borderline high, and
normal cholesterol levels, reduction in total and LDL-cholesterol
concentrations, following probiotics-intervention, was reported [20].
Finally, significant lowering of HbA1c, fasting blood glucose, and
fasting plasma insulin concentrations, and amelioration of insulin
resistance have been seen after interventions with probiotics-
containing products in type 2 diabetes [21,22]. To the best of our
knowledge, the health effects of probiotics amongst individuals with
type 1 diabetes, a population at high risk of vascular complications,
have not been investigated.
The aim of the current study was to assess the cross-sectional
associations between reported use of probiotics-containing food
products or supplements and selected health parameters in a large
population of well-defined individuals with type 1 diabetes.
Materials and Methods
Study subjects
Study subjects were individuals with type 1 diabetes participating in
the FinnDiane Study. Type 1 diabetes was presumed if age at diabetes
onset was below 35 years and if permanent insulin treatment was
initiated within one year of the diagnosis. Included, in the current
analyses, were all individuals who had completed the diet
questionnaire within two years from the study visit [median
(interquartile range) interval between the study visit and the
completion of diet questionnaire was 6 (0-61) days]. Those with end-
stage renal disease (undergoing dialysis or with a kidney
transplantation) were excluded from the analyses. In all, data from a
total of 1039 individuals (mean age 46 ± 14 years, 45% men) were
included. The study protocol was approved by the Ethics Committee of
the Helsinki University Central Hospital. Study subjects provided
written informed consent prior to participation.
Clinical measurements
During the FinnDiane study visit, participants’ height and weight
were measured in light clothing, and body mass index was calculated
(BMI; kg/m2). Overweight and obesity were defined as BMI ≥ 25
kg/m2 and ≥ 30 kg/m2, respectively. Waist and hip circumferences were
measured using an inelastic tape measure. Following a minimum of
ten-minute rest, blood pressure was measured while seated. A second
measure was performed with a two-minute interval. Mean of the two
measurements was used in the analyses. HbA1c was determined locally
using standardized assays. Serum lipid and lipoprotein concentrations
were measured centrally at the research laboratory of the Helsinki
University Central Hospital. Serum triglyceride concentration was
measured using a Konelab 60i analyser (Thermo Fisher Scientific Inc.,
Waltham, MA, USA), and serum HDL-cholesterol concentration was
measured with a HTS 7000 plus Bio Assay Reader (Perkin Elmer Inc.,
Waltham, MA, USA). Renal status was assessed based on the urinary
albumin excretion rate (AER) in at least two out of three timed 24-h or
overnight urine collections. Diabetic nephropathy was assumed when
AER ≥ 200 μg/min or ≥ 300 mg/24 h. Serum hs-CRP concentration
was measured by immunoassay (Modular analyzer, Roche). Individuals
with hs-CRP values above 10 mg/l were excluded from the hs-CRP
analyses, as they likely had an acute infection. Smoking was self-
reported. The attending physician recorded medication use on a
standardized questionnaire. From these questionnaires, data regarding
antihypertensive and blood lipid medication were collected.
Information on the use of antibiotics within 6 months prior to the
study visit was obtained from the Drug Prescription Register of the
Social Insurance Institute of Finland.
Metabolic syndrome
The criteria established by International Diabetes Federation Task
Force on Epidemiology and Prevention; National Heart, Lung, and
Blood Institute; American Heart Association; World Heart Federation;
International Atherosclerosis Society; and International Association
for the Study of Obesity was used to define the metabolic syndrome
[23]. Accordingly, metabolic syndrome exists when the minimum of
three of the following components coexist: waist circumference ≥ 94
cm in men and ≥ 80 cm in women, triglyceride concentration ≥ 1.70
mmol/l (or medication to lower triglyceride concentration), HDL-
cholesterol concentration <1.00 mmol/l in men and <1.30 mmol/l in
women (or medication to increase HDL-cholesterol concentration),
blood pressure ≥ 130/85 mmHg (or antihypertensive medication), and
fasting blood glucose concentration ≥ 6.11 mmol/l. Diagnosed with
type 1 diabetes, all patients were defined to fulfil the hyperglycaemia
criterion.
Dietary intake
Data on the participants’ dietary intake were collected using two
separate methods, as previously described [24]. In short, at the study
visit, participants were provided with a validated [25] diet
questionnaire. With this questionnaire, we aimed at obtaining an
overview of the subjects’ dietary intake. Amongst others, we enquired
the types of milk, bread, spread, and cooking fat typically consumed.
As part of the questionnaire, a short food frequency questionnaire was
included. Of interest for the current study, we also queried about the
use of probiotics-containing food products or supplements over the
past month (no/yes, if yes provide the trade name and amount or dose
consumed). Upon returning the diet questionnaire, subjects were sent
a 3-day exercise and food record. In this record, along with reporting
physical activity and insulin administration, all foods and drinks
consumed over the allocated consecutive days (two weekdays and one
weekend day), were recorded. Another 3-day food record was
completed with a 10-week interval. Up to two reminders were sent to
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non-responders. Dietary composition of the food record entries was
analysed using the Diet 3.2 software (version 1.4.6.2, AIVO, Turku,
Finland) and, from August 2014 onwards, AivoDiet software (version
2.0.2.3, AIVO, Turku, Finland), both based on the Finnish National
Food Composition Database. In the analyses the health markers of
individuals, reporting (Probioticsyes) and not reporting (Probioticsno)
the use of probiotics-containing food products or supplements, either
in the diet questionnaire or in the food record, were compared.
Physical activity
Leisure-time physical activity (LTPA) was estimated using a
validated questionnaire, as previously described [26]. In this form,
participants reported frequency, single session duration, and intensity
of a number of most typical physical activities. Based on these reports,
weekly LTPA was calculated as the metabolic equivalent of task hours
(MET h/week).
Statistical analyses
Descriptive statistics are reported as percentages for categorical
data, mean ± standard deviation for continuous normally distributed
data, and median (interquartile range) for continuous non-normally
distributed data. The respective between-group comparisons were
done using Chi-squared test, independent samples t-test, and Mann-
Whitney U-test. The difference in the outcome variables, between the
two probiotics-groups, were further tested in the multivariable models.
For dichotomous outcome variables, logistic regression analyses were
applied, while with continuous variables, generalised linear regression
analyses were conducted. Analyses of waist circumference and HDL-
cholesterol concentration were conducted separately for men and
women, as there are sex-specific cut off values for these variables also
in the definition of the metabolic syndrome. HbA1c analyses were
conducted separately for normal-weight and overweight or obese
individuals, as there is indication that probiotics may have distinctive
effects depending on the adiposity [27]. Confounders were selected to
the multivariable models if they significantly differed between the two
groups or probiotics-consumption, or if they were considered to
significantly contribute to the outcome variable (e.g., lipid lowering
medication in blood lipid analyses, and antihypertensive medication in
blood pressure analyses). A two-tailed P value <0.05 was considered
statistically significant. All data were analysed using IBM SPSS
Statistics for Windows, Version 22.0 (IBM Corp, Armonk, NY, USA).
Results
Of the 1039 participants, 403 (39%) reported using probiotics-
containing food stuffs or supplements (Probioticsyes, Table 1). In this
group, the proportion of men and those with diabetic nephropathy was
lower. No differences were observed, between the groups, in mean age,
the frequency of antibiotic use within 6 months prior to the study visit,
the frequency of smoking, or the level of physical activity.
Probioticsno n=636 (61%) Probioticsyes n=403 (39%) P
Men, % 51 35 <0.01
Age, years 46 ± 14 46 ± 13 0.45
Use of antibioticsa, % 30 32 0.439
Diabetic nephropathy, % 14 9 0.008
Smoking, % 14 12 0.565
Physical activity, MET h/week 12 (2-27) 13 (1-28) 0.641
Dichotomous outcome variables
Overweight or obese, % 58 49 0.006
Metabolic syndrome, % 70 58 <0.001
MS-Blood pressure component,
% 81 72 0.002
MS-HDL-cholesterol component,
% 47 35 <0.001
MS-TG component, % 47 33 <0.001
MS-waist component, % 58 51 0.032
Continuous outcome variables
HbA1c (NW), mmol/mol 64 (57-75) 62 (54-69) 0.01
HbA1c (OW/OB), mmol/mol 65 (57-74) 66 (60-74) 0.277
HbA1c (NW), % 8.0 (7.4-9.0) 7.8 (7.1-8.5) 0.01
HbA1c (OW/OB), % 8.1 (7.4-8.9) 8.2 (7.6-8.9) 0.277
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Table 1: Participant characteristics divided by the reported use of probiotics. 
BMI, kg/m2 25.9 (23.3-28.6) 25.0 (23.0-27.8) 0.011
Waist-to-hip ratio 0.89 (0.83-0.96) 0.87 (0.82-0.92) <0.001
Waist circumference (men), cm 94 (86-102) 92 (84-98) 0.041
Waist circumference (women), cm 84 (77-92) 82 (75-91) 0.093
Systolic blood pressure, mmHg 136 (126-149) 133 (124-147) 0.032
Diastolic blood pressure, mmHg 77 (71-84) 76 (70-83) 0.09
Total cholesterol, mmol/l 4.6 (4.0-5.2) 4.6 (4.1-5.1) 0.582
HDL-cholesterol (men), mmol/l 1.42 (1.17-1.67) 1.50 (1.21-1.79) 0.072
HDL-cholesterol (women), mmol/l 1.64 (1.35-1.96) 1.72 (1.45-2.09) 0.026
TG, mmol/l 0.99 (0.76-1.42) 0.91 (0.69-1.23) <0.001
TG-HDL-cholesterol ratio 0.65 (0.43-1.08) 0.56 (0.37-0.82) <0.001
hs-CRP, mg/l 1.11 (0.54-2.53) 0.97 (0.51-2.27) 0.212
Data are presented as frequencies (%) for categorical variables, mean± standard deviation, or median (inter-quartile range). Between-group 
comparisons are conducted using Chi squared test, independent samples t-test, and Mann-Whitney U-test, respectively. aUse of antibiotics within 
6 months prior to the study visit. MET, metabolic equivalent of task, a measure of physical activity; MS, metabolic syndrome; HDL, high density 
lipoprotein; TG, triglyceride; NW, normal-weight (BMI <25 kg/m2); OW/OB, overweight or obese (BMI ≥ 25 kg/m2); BMI, body mass index; hs-
CRP, high-sensitivity C-reactive protein.
between the two groups. Of the blood lipid variables, the triglyceride
concentration and the TG-HDL-cholesterol ratio were lower in the
Probioticsyes group. In women reporting the use of probiotics, the
HDL-cholesterol concentration was higher. Finally, of the continuous
outcome variables, systolic blood pressure was lower amongst those
using probiotics.
No differences were observed in the dietary intake of total energy,
macronutrients, and fibre between those using and not using
probiotics (Table 2). Moreover, the relative distribution of fatty acid
intakes was similar between the groups. However, significantly higher
median sucrose intake was observed amongst those using probiotics.
Probioticsno n=636 (61%) Probioticsyes n=403(39%) P
Energy, kJ 7705 (6426-9219) 7677 (6371-8998) 0.745
Energy, kcal 1841 (1536-2204) 1835 (1523-2150) 0.742
Carbohydrates, E% 43 (38-48) 43 (39-48) 0.682
Sucrose, g 29.1 (20.2-48.4) 34.5 (22.2-48.9) 0.027
Proteins, E% 17 (15-19) 17 (15-19) 0.883
Fats, E% 36 (31-40) 35 (31-40) 0.252
PUFA, E% 6 (5-7) 6 (5-7) 0.774
SAFA, E% 13 ± 3 12 ± 3 0.295
MUFA, E% 12 (10-14) 12 (10-14) 0.267
Alcohol, E% 0.7 (0-3.1) 1.1 (0-3.5) 0.345
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Compared to those reporting the use of probiotics, various 
overweight-related measures were more prevalent amongst those not 
using probiotics (Table 1). For example, BMI and waist-to-hip ratio 
were higher in the Probioticsno group. Moreover, the prevalence of 
overweight or obesity, and the frequency of fulfilling the waist 
component of the metabolic syndrome were higher in the Probioticsno
group. In addition, the metabolic syndrome and all the remaining 
components of the metabolic syndrome were more prevalent amongst 
those who reported not using probiotics.
In the normal-weight individuals, the median glycaemic control was 
significantly better in the group using probiotics (Table 1). However, in 
overweight or obese individuals, no difference in HbA1c was observed
Table 2: Dietary intake divided by the reported use of probiotics.
Total fibre, g 20.7 (15.8-26.4) 21.3 (16.5-27.1) 0.401
Soluble fibre, g 4.8 (3.7-6.2) 5.1 (3.9-6.5) 0.198
Data are presented as median (interquartile range) or mean ± standard deviation. Between-group comparisons with Mann-Whitney U-test 
or independent samples t-test, respectively. E%, percentage of total energy intake.
In the logistic regression analyses, adjusting for age, sex,
nephropathy status, sucrose intake, physical activity, and smoking, the
use of probiotics was associated with a 35% (P=0.006) lower odds of
overweight or obesity and a 40% (P=0.003) lower odds of the
metabolic syndrome (Table 3). Similarly, the odds of fulfilling the
blood pressure, HDL-cholesterol, triglyceride, and waist components
of the metabolic syndrome were 42% (P=0.009), 32% (P=0.025), 33%
(P=0.019), and 34% (P=0.013) lower, respectively, amongst those using
probiotics.
Model 1 Model 2
B Exp(B) 95% CI for Exp(B) P B Exp(B) 95% CI for Exp(B) P
OW/OB -0.30 0.74 0.57-0.96 0.022 -0.43 0.65 0.48-0.89 0.006
MS -0.50 0.61 0.46-0.81 0.001 -0.52 0.60 0.42-0.84 0.003
MS/BP -0.37 0.69 0.49-0.97 0.033 -0.54 0.58 0.39-0.88 0.009
MS/HDL -0.42 0.66 0.50-0.87 0.003 -0.38 0.68 0.49-0.95 0.025
MS/TG -0.48 0.62 0.47-0.83 0.001 -0.40 0.67 0.48-0.94 0.019
MS/waist -0.34 0.71 0.55-0.93 0.011 -0.41 0.66 0.48-0.92 0.013
Model 1 is adjusted for age, sex, and nephropathy status. Model 2 is further adjusted for sucrose intake, physical activity and smoking. CI, 
confidence interval; OW/OB, overweight or obese (BMI ≥ 25 kg/m2); MS, metabolic syndrome; MS/BP, blood pressure component of the 
metabolic syndrome; MS/HDL, HDL-cholesterol component of the metabolic syndrome; MS/TG, triglyceride component of the metabolic 
syndrome; MS/waist, waist component of the metabolic syndrome. Logistic regression.
Of the continuous outcome variables the use of probiotics was, in
the fully adjusted models, associated with lower BMI (P=0.049), waist-
to-hip ratio (P=0.002), total cholesterol concentration (P=0.049),
triglyceride concentration (P=0.001), and TG-HDL-cholesterol ratio
(P<0.001) (Table 4). Moreover, among the normal-weight individuals,
use of probiotics was associated with better glycaemic control
(P=0.026), and in women it was associated with smaller waist
circumference (P=0.009). However, in the multivariable models, the
use of probiotics was no longer associated with systolic blood pressure
or HDL-cholesterol concentration.
Model 1 Model 2
B (95% Wald CI) Probiotics
no
Mean (SE)
Probioticsyes
Mean (SE) P B (95% Wald CI)
Probioticsno
Mean (SE)
Probioticsyes
Mean (SE) P
HbA1c (NW),
mmol/mol, % -0.31 (-0.55--0.07)
67 (1.07) 64 (1.35)
0.011 -0.31 (-0.58--0.04)
66 (1.29) 63 (1.47)
0.026
8.27 (0.08) 7.96 (0.09) 8.20 (0.10) 7.90 (0.10)
HbA1c (OW/OB),
mmol/mol, % 0.04 (-0.16-0.23)
67 (0.80) 67 (1.21)
0.703 0.05 (-0.17-0.28)
66 (0.90) 67 (1.34)
0.66
8.24 (0.06) 8.28 (0.08) 8.19 (0.07) 8.24 (0.09)
BMI, kg/m2 -0.47 (-0.98-0.04) 26.2 (0.16) 25.8 (0.20) 0.07 -0.60 (-1.19--0.01) 26.3 (0.19) 25.7 (0.23) 0.049
WHR -0.01 (-0.02--0.01) 0.89 (0.01) 0.88 (0.01) 0.037 -0.02 (-0.03--0.01) 0.89 (0.01) 0.88 (0.01) 0.002
Waist (men), cm -2.53 (-4.84--0.22) 94.9 (0.65) 92.3 (0.98) 0.032 -1.91 (-4.60-0.79) 94.8 (0.79) 92.9 (1.12) 0.165
Waist (women),
cm -1.28 (-3.28-0.73) 85.3 (0.69) 84.1 (0.76) 0.212 -2.91 (-5.11--0.72) 85.9 (0.76) 83.0 (0.81) 0.009
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Table 3: Association between probiotic use and selected dichotomous health markers. 
Table 4: Association between the use of probiotics and selected continuous health markers.
SBP, mmHg -0.43 (-2.41-1.55) 137 (0.62) 137 (0.79) 0.667 -1.94 (-4.27-0.39) 138 (0.75) 136 (0.91) 0.103
DBP, mmHg -0.67 (-1.84- 0.50) 77 (0.37) 77 (0.47) 0.263 -0.96 (-2.37-0.45) 77 (0.45) 76 (0.55) 0.182
TC, mmol/l -0.09 (-0.20-0.02) 4.7 (0.03) 4.6 (0.04) 0.109 -0.13 (-0.25--0.01) 4.69 (0.04) 4.56 (0.05) 0.049
HDL (men),
mmol/l 0.06 (-0.03-0.14) 1.48 (0.02) 1.53 (0.04) 0.212 0.01 (-0.10-0.11) 1.52 (0.03) 1.52 (0.04) 0.947
HDL (women),
mmol/l 0.07 (0.01-0.15) 1.70 (0.03) 1.77 (0.03) 0.045 0.07 (-0.01-0.16) 1.71 (0.03) 1.79 (0.03) 0.085
TG, mmol/l -0.16 (-0.26--0.06) 1.24 (0.03) 1.08 (0.04) 0.002 -0.17 (-0.26--0.07) 1.19 (0.03) 1.02 (0.04) 0.001
TG/HDL -0.13 (-0.21--0.04) 0.87 (0.03) 0.74 (0.03) 0.004 -0.15 (-0.23--0.06) 0.82 (0.03) 0.68 (0.03) <0.001
hs-CRP, mg/l -0.24 (-0.49-0.01) 1.91 (0.08) 1.67 (0.10) 0.058 -0.27 (-0.56-0.02) 1.90 (0.09) 1.63 (0.11) 0.067
Model 1 is adjusted for age, sex, and nephropathy status. Model 2 is further adjusted for sucrose intake, physical activity and smoking. Final blood 
pressure models are additionally adjusted for the use of antihypertensive medication; blood lipid and hs-CRP models are additionally adjusted for 
the use of lipid lowering medication. CI, confidence interval; SE, standard error; NW, normal-weight (BMI 25 <kg/m2); OW/OB, overweight or 
obese (BMI ≥ 25 kg/m2); BMI, body mass index; WHR, waist-to-hip ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total 
cholesterol; HDL, high-density lipoprotein cholesterol; TG, triglyceride; TG/HDL, triglyceride-high-density lipoprotein cholesterol ratio; hs-CRP, 
high-sensitivity C-reactive protein. Generalized linear model.
Discussion
In the current study, we observed that the use of probiotics-
containing food products or supplements was associated with a
number of beneficial health markers in type 1 diabetes. In particular,
the use of probiotics was associated with lower odds of overweight or
obesity. Also the odds of metabolic syndrome, and its blood pressure,
HDL-cholesterol, triglyceride, and waist components were significantly
lower amongst those using probiotics. Moreover, in normal-weight
individuals, the use of probiotics was associated with better glycaemic
control.
While, to our knowledge, this is the first study to focus on the health
effects of probiotics in individuals with type 1 diabetes, a number of
studies have been conducted in other populations. Of interest in
diabetes, probiotics may improve glycaemic control. The exact
mechanisms by which probiotics could affect glycaemia, is not known.
However, it has been speculated that beneficial gut bacteria could
increase the secretion of glucagon-like peptide 1 which would
subsequently improve carbohydrate metabolism [28]. Other proposed
mechanisms are related to improved intestinal permeability, regulation
of the immune system, and reduction of Toll-like receptor 4 signalling.
In their meta-analysis, Li et al. reported significant reduction in fasting
blood glucose levels, following probiotics-intervention, in patients with
type 2 diabetes [28]. However, no effect was observed in HbA1c. As a
long-term measure of glycaemia, the included intervention trials
(mostly ≤ 8 weeks) may have been too short to show significant
changes in HbA1c. In contrast, Sun and Buys reported, in their meta-
analysis of individuals with type 2 diabetes or with diabetes-associated
risk factors, a significant reduction in the participants’ HbA1c following
6-12 weeks’ probiotic intervention [29]. In their study, the glycaemia-
reducing effect of probiotics was most pronounced in those with
diabetes, and when multiple strains were used. Interestingly, Firouzi et
al. reported, in a population of individuals with type 2 diabetes, that
among normal-weight participants a 12-week probiotics-intervention
resulted in greater improvements in HbA1c than in those overweight or
obese [27]. Encouraged by these observations, we also investigated the
glycaemic control separately in normal-weight and in overweight/
obese. Indeed, in the current study, the use of probiotics was associated
with lower HbA1c levels in the normal-weight individuals, while no
association was observed amongst those with higher BMIs. While the
mechanism behind this phenomenon is not known, the differences
frequently observed in the Bacteroidetes to Firmicutes -ratio in the gut
of obese and lean subjects, could be responsible for the observed
differences. Also, it has been speculated that the dosage of probiotics,
commonly used, may not be sufficient to produce beneficial effects in
glycaemia in obese but, instead, weight-based dosages may be required
[27].
The association between gut microbiota and obesity has been shown
both in animals and humans [30]. Beyond the before-mentioned
differences in the Bacteroidetes to Firmicutes ratio, it has also been
shown that compared to lean, obese individuals display decreased
diversity of the gut microbiota; beneficial changes take place in the
composition of the fecal microbiota during weight loss interventions;
and a more diverse microbial community is observed amongst subjects
with greater weight loss [30]. Indeed, there is some indication that the
so called “obese microbiome” has an increased capacity to harvest
energy from the diet, which in due course could contribute to obesity
[31]. Our results fit well with previous observations as the reported use
of probiotics was favourably associated with many of the body weight-
related variables.
According to one meta-analysis of randomized controlled trials in
type 2 diabetes, probiotics-intervention increased HDL-cholesterol
concentration, but had no significant effect on LDL-cholesterol, total
cholesterol or triglyceride concentration [28]. Another meta-analysis
of randomized controlled trials among subjects with high, borderline
high, or normal cholesterol levels, reported significant reductions in
total cholesterol and LDL-cholesterol concentrations, but found no
effects in HDL-cholesterol and triglyceride concentrations [20]. There
are a number of proposed mechanisms by which gut bacteria are
anticipated to affect circulating lipid concentrations. Probiotic bacteria
may, for example, interfere with the absorption of cholesterol from the
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intestine by directly assimilating it and using it as a substrate for
bacterial growth [32]. Bacteria may also deconjugate bile acids, which
makes them less likely to be reabsorbed into the enterohepatic
circulation [33]. Increased excretion of bile acids subsequently
increases the need for de novo synthesis of cholesterol-containing bile
acids, which reduces the total amount of cholesterol in the circulation.
Finally, the short-chain fatty acids (SCFAs) produced by the probiotics
and quickly absorbed from the intestine, may inhibit hepatic
cholesterol synthesis or participate in the redistribution of cholesterol
from plasma to the liver [33]. In the current study, consumption of
probiotics was associated with slightly but significantly lower total
cholesterol and triglyceride concentration, and also a lower
triglyceride–HDL-cholesterol ratio, compared to the group not using
probiotics. We were not able to find any previous reports on the
association between probiotics and triglyceride–HDL-cholesterol ratio.
This ratio is, however, a marker of insulin resistance. An increase in the
triglyceride-HDL-cholesterol ratio is associated with parameters of
cardiovascular risk, and it may predict the development of coronary
heart disease and cardiovascular mortality [34]. Keeping the ratio
down may, thus, be relevant also in type 1 diabetes.
The effect of probiotics on blood pressure has also been investigated,
and according to a meta-analysis of such randomized controlled trials,
probiotics-intervention significantly reduced both systolic and diastolic
blood pressure in adult subjects with or without hypertension [19].
Importantly, interventions of a duration of at least 8 weeks were
required for the observed effects. Also, those with higher blood
pressure at baseline, seemed to benefit the most from the intervention,
and the blood pressure-reducing effects were more evident in trials
using multiple species of probiotics, as opposed to single species.
Probiotics may affect blood pressure via various proposed mechanisms
[19]. Gut microbiota-derived SCFAs may take part in the regulation of
the renin-angiotensin system, or the probiotics may increase the
absorption of nutrients and phytoestrogens with vasodilatory effects.
The blood-pressure reducing effect of probiotics may also result from
the reduction in adiposity. In the current study, while those reporting
the use of probiotics had significantly lower systolic blood pressure, the
statistical significance of this difference did not persist after controlling
for confounding factors. Despite this, those reporting using probiotics
had lower odds of fulfilling the blood pressure component of the
metabolic syndrome. In this entity, not only systolic blood pressure,
but also diastolic blood pressure and the use of antihypertensive
medication are, however, taken into account.
It has been suggested that the SCFAs, produced by the beneficial gut
microbes, may prevent low-grade inflammation via maintaining
intestinal integrity [35]. A meta-analysis of the ability of probiotics-
intervention to reduce CRP levels, in type 2 diabetes, showed an overall
non-significant effect [35]. A sub-group analysis in another meta-
analysis suggested, however, that a high probiotic dose, longer
intervention duration, and the use of multiple strains of probiotics
would, indeed, have anti-inflammatory effects [36]. In the current
study, the reported use of probiotics was not associated with hs-CRP
levels in type 1 diabetes. In the light of the previous reports, our
observations could suggest, for example, that the use of probiotics, in
this population, is sporadic rather than regular.
This study has a number of limitations that should be discussed. The
cross-sectional nature of the study poses a major limitation as it
prevents us from making any conclusions about causality between the
use of probiotics and the health markers. Self-reporting the use of
probiotics is another limitation. Not all individuals may, for example,
be aware that the products they use contain probiotics, and will
subsequently not report their use. Also, for some participants the
reported use of probiotics, at the time of data collection, may have only
been an occasional event and does not reflect a more continuous habit.
Such an occasional act may not be sufficient to influence the measured
variables. Based on the collected data, we cannot calculate the doses of
probiotics used. Also, in many cases, the actual strain or strains used
was not known. Compared to many intervention trials conducted in
this field, the sample size in the current study was, however, much
larger. Moreover, our study group is fairly homogenous, as participants
were all diagnosed with type 1 diabetes. Finally it has to be
acknowledged that more health-conscious individuals may not only
consume probiotics but may also have overall healthier lifestyles that
may affect the outcome variables. While we adjusted the models with
factors such as physical activity, smoking, and dietary intake, we
cannot rule out potential residual confounding.
In conclusion, the reported use of probiotics among individuals with
type 1 diabetes, was beneficially associated with a number of health
markers such as glycaemia, metabolic syndrome, obesity, and lipid
parameters. Our results suggest that the use of probiotics could reduce
many of the traditional risk factors related to the emergence of diabetic
complications. Randomized controlled trials of sufficient duration,
preferably using multiple strains of probiotics, are required in order to
affirm these observations.
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